SLN
Silence Therapeutics plc
$9.95
-0.20 (-1.97%)
At close · Jul 8
Market Cap
$1.39B
Shares
141,703,840
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.95
Open$10.05
Day$9.42–10.18
52W$4.19–11.06
Avg vol 30d465K
Short int2.1M · 1.5% float · 8.6d
Short vol17%
Last earningsFeb 27, 2025
DataSep 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+56%
above
Price vs 50-day avg
+33%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+60%
trailing
6-month return
+68%
trailing
YTD return
+64%
this year
Relative strength
+61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
1 of 56 funds reported for Jun 30 · net +1.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.46% of float · ▲ +0.4% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−99%
Y/Y
Gross margin
62%
contracting
EPS growth
−91%
Y/Y
Free cash flow
$-62.3M
Balance sheet
$11.3M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+56%
Bullish
Price vs 50-day avg
+33%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
1 of 56 funds reported for Jun 30 · net +1.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.46% of float · ▲ +0.4% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $10 · 84%
52-wk high $11
vs 200-day avg +56%
vs 50-day avg +33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLN
this stock
Silence Therapeutics plc
|
$1.39B | +63.7% | +46.1% | — | 1.5% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLN | -9.4% | +59.7% | +68.4% | -9.4% | +63.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -9.2% | +58.9% | +60.9% | -9.2% | +54.3% |